Refine by
Maternal Death Suppliers & Manufacturers
5 companies found
based inLeichhardt, AUSTRALIA
Baymatob is an Australian company specialising in the development of medical devices. The company was founded after the traumatic birth experience of CEO, Sarah McDonald, with her second child. It was this experience that made clear the need to do ...
Oli PPH is Baymatob's first AI-guided medical product based on the Oli maternity sensor, monitoring and diagnostic platform. Oli PPH is the only product to have ever demonstrated the ability to identify women who are at higher risk ...
based inSaint-Prex, SWITZERLAND
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty ...
based inBellingham, WASHINGTON (USA)
Public Health Online began in early 2014 in response to what we saw as a need for a resource to serve aspiring and practicing public health professionals across all disciplines. Our vision was to provide students, parents and general readers with ...
based inSydney, AUSTRALIA
Uscom Limited (UCM) is an Australian founded, ASX listed innovative medical technology company specialising in development and global marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate ...
USCOM 1A uses advanced Doppler hemodynamics to monitor cardiac blood flow. Stroke Volume (SV) monitoring changes the way we manage fluid, inotropes, and vaso-actives, and how we diagnose and manage sepsis, heart failure and ...
based inSilver Spring, MARYLAND (USA)
We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical ...
Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional ...